<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02537054</url>
  </required_header>
  <id_info>
    <org_study_id>AUG-201202-EyNeP</org_study_id>
    <nct_id>NCT02537054</nct_id>
  </id_info>
  <brief_title>Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)</brief_title>
  <acronym>EyNeP</acronym>
  <official_title>Intravitreal Aflibercept (Eylea) for Therapy of Choroidal Neovascularization (CNV) and Fibrovascular Proliferation (FVP) in Patients With Pseudoxanthoma Elasticum (PXE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Aflibercept (Eylea) is effective in the
      treatment of choroidal neovascularization and fibrovascular proliferation in patients with
      pseudoxanthoma elasticum (PXE) in terms of preservation or improvement of visual acuity.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in distance best corrected visual acuity between end-of study visit and screening visit</measure>
    <time_frame>Screening visit (day -28 - 0) and end-of-study visit (day 360 +/- 7)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in light increment sensitivity of central visual field between end-of study visit and screening visit measured by microperimetry</measure>
    <time_frame>Screening visit (day -28 - 0) and end-of-study visit (day 360 +/- 7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in chorioretinal neovascularization and leakage measured by angiography between end-of study visit and screening visit</measure>
    <time_frame>Screening visit (day -28 - 0) and end-of-study visit (day 360 +/- 7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sub- and intraretinal und subpigmentepithelial fluids assessed using optical coherence tomography (OCT)</measure>
    <time_frame>Screening visit (day -28 - 0) and end-of-study visit (day 360 +/- 7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of fibrovascular proliferation on optical coherence tomography (OCT) imaging</measure>
    <time_frame>Screening visit (day -28 - 0) and end-of-study visit (day 360 +/- 7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes fundus autofluorescence images using a confocal scanning laser ophthalmoscope (cSLO)</measure>
    <time_frame>Screening visit (day -28 - 0) and end-of-study visit (day 360 +/- 7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the health status of the total population measured by quality of life questionnaire Visual Function Questionnaire (VFQ)-25</measure>
    <time_frame>Screening visit (day -28 - 0) and end-of-study visit (day 360 +/- 7)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Pseudoxanthoma Elasticum</condition>
  <arm_group>
    <arm_group_label>Aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg/ dose (pro re nata, maximum 1 dose/ month), intravitreal use</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Intravitreal injection</description>
    <arm_group_label>Aflibercept</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of PXE by moleculargenetic diagnosis and/or skin biopsy

          -  Diagnosed CNV or FVP

          -  Age 18-65 years

          -  Voluntary participation in this study as proven by written informed consent

          -  Ability to follow study instructions and likely to attend and complete all required
             visits

          -  Best corrected visual acuity between 20/400 and 20/20 at treated eye

          -  Male and female patients with childbearing potential must use an approved
             contraceptive method (Pearl Index &lt; 1) before and during the trial

          -  Pre-menopausal female patients with childbearing potential: a negative pregnancy test
             must be obtained

        Exclusion Criteria:

          -  Subject is unable to understand the nature, scope, significance and consequences of
             this clinical trial

          -  Patients with known allergy or hypersensitivity to Eylea or preparations with similar
             chemical structure

          -  Treatment in another clinical trial with therapeutic intervention or use of any other
             investigational medicinal product (IMP) during the trial of within 30 days before
             enrolment

          -  Known or persistent abuse of medication, drugs or alcohol

          -  Women who are pregnant or breast feeding

          -  Lack of eligibility at discretion of the investigator

          -  Ocular operations within a month prior to enrolment

          -  Non-controlled glaucoma

          -  Active intraocular inflammation or inflammation of ocular adnexa

          -  Other diseases resulting in distinct visual constraint

          -  Distinct opacification of optical media

          -  Distinct subretinal fibrosis and /or atrophy that prevents a relevant treatment effect
             by Aflibercept at discretion of investigator

          -  Serious cardiovascular problems or stroke within 6 months before enrolment

          -  Simultaneous use of other Vascular Endothelial Growth Factor (VEGF)-inhibiting
             medication (systemic or ocular) within a month prior to enrolment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank G. Holz, MD, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic Bonn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology, Universtiy of Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2015</study_first_submitted>
  <study_first_submitted_qc>August 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2015</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Frank G. Holz</investigator_full_name>
    <investigator_title>Prof. Dr. med. Frank G. Holz</investigator_title>
  </responsible_party>
  <keyword>Choroidal neovascularization</keyword>
  <keyword>Angioid streaks</keyword>
  <keyword>Pseudoxanthoma Elasticum</keyword>
  <keyword>vascular endothelial growth factor</keyword>
  <keyword>aflibercept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Pseudoxanthoma Elasticum</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

